Tanta Research Team, Tanta, El-Gharbia, Egypt.
Harvard Medical School, Boston, MA, USA.
Eye (Lond). 2023 Nov;37(16):3322-3333. doi: 10.1038/s41433-023-02524-w. Epub 2023 Apr 18.
We conducted this research to determine the prevalence rate and presentation patterns with microcystic macular oedema (MMO) in glaucoma patients. The protocol was pre-registered on PROSPERO ( CRD42022316367 ). PubMed, Scopus, Web of Science, EMBASE, ProQuest, EBSCOHost, CENTRAL, clinicaltrials.gov, and Google Scholar were searched for articles reporting MMO in glaucoma patients. The primary outcome was the prevalence of MMO, while secondary outcomes included the comparison between MMO and non-MMO in terms of patients' characteristics (age, gender), glaucoma stage, and ocular parameters (axial length (AL), intraocular pressure, mean deviation, spherical equivalent). Data are reported as mean difference (MD) or log odds ratio (logOR) along with their corresponding 95% confidence intervals (CI) for continuous and dichotomous outcomes, respectively. The quality of included studies was assessed using the NIH tool, and the certainty of evidence was assessed using GRADE framework. Ten studies (2128 eyes) were included, revealing an overall prevalence rate of MMO of 8% (95%CI: 5-12%). When compared to non-MMO group, MMO was associated with lower age (MD = -5.91; 95%CI: -6.02: -5.20), greater risk of advanced glaucoma stage (LogOR=1.41; 95%CI: 0.72: 2.09), and lower mean deviation of the visual field (MD = -5.00; 95%CI: -7.01: -2.99). No significant difference was noted between both groups in terms of gender, axial length, or spherical equivalent. Three studies had good quality while seven had poor quality. MMO is a prevalent observation in glaucoma patients and is associated with patients' age and stage of the disease. However, the certainty of evidence remains very low.
我们进行这项研究是为了确定青光眼患者中微囊型黄斑水肿（MMO）的患病率和表现模式。该方案已在 PROSPERO（CRD42022316367）上预先注册。我们检索了 PubMed、Scopus、Web of Science、EMBASE、ProQuest、EBSCOHost、CENTRAL、clinicaltrials.gov 和 Google Scholar 上的文章，以报告青光眼患者中 MMO 的情况。主要结果是 MMO 的患病率，次要结果包括 MMO 与非 MMO 之间在患者特征（年龄、性别）、青光眼阶段和眼部参数（眼轴长度（AL）、眼内压、平均偏差、等效球镜）方面的比较。数据以连续和二分类结果的均值差（MD）或对数优势比（logOR）及其相应的 95%置信区间（CI）报告。使用 NIH 工具评估纳入研究的质量，并使用 GRADE 框架评估证据的确定性。纳入了 10 项研究（2128 只眼），发现 MMO 的总体患病率为 8%（95%CI：5-12%）。与非 MMO 组相比，MMO 与较低的年龄（MD=-5.91；95%CI：-6.02：-5.20）、更高级别的青光眼阶段（LogOR=1.41；95%CI：0.72：2.09）和更低的视野平均偏差（MD=-5.00；95%CI：-7.01：-2.99）相关。两组在性别、眼轴长度或等效球镜方面无显著差异。有三项研究质量良好，七项研究质量较差。MMO 是青光眼患者中常见的观察结果，与患者的年龄和疾病阶段有关。然而，证据的确定性仍然非常低。
